AllAnalyst Report
Morningstar•March 07, 2024
Morningstar•March 07, 2024Sanofi: Led by Dupixent, Sanofi's Solid Immunology Position Helps Support Steady Long-Term Growth
Summary
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared wit
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeActions
Download Full ReportRelated Reports
- Analyst Report: AstraZeneca PLCApr 26, 2024 •
AZN
- Analyst Report: AstraZeneca PLCApr 26, 2024 •
AZN
- Analyst Report: Merck & Co., Inc.Apr 25, 2024 •
MRK
- Analyst Report: Bristol-Myers Squibb CompanyApr 25, 2024 •
BMY
- Analyst Report: Biogen Inc.Apr 24, 2024 •
BIIB
Analyst Profile
Damien Conover
Sector DirectorDamien Conover, CFA, is director of healthcare equity research for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He is also director of equity strategy, responsible for helping to shape, package, and surface research based on Morningstar's investment philosophy by working closely with the firm's North American sector strategists and directors.Before joining Morningstar in 2007, Conover was an equity research analyst covering the healthcare sector for Raymond James, Bank of Montreal, and Tucker Anthony.Conover holds bachelor's and master's degrees in finance from the University of Wisconsin and was a member of its Applied Security Analysis Program. He also holds the Chartered Financial Analyst® designation.